

**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. - 11. (Cancelled).

12. (Original) An inhalable solid pharmaceutical formulation comprising  
(a) an active ingredient substance susceptible to chemical interaction with lactose, said active ingredient substance selected from:  
3-(4-[[6-((2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino)hexyl]oxy]butyl) benzenesulfonamide;  
3-(3-[[7-((2*R*)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl)-amino]heptyl[oxy]propyl)benzenesulfonamide;  
4-((1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol and  
4-((1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol,  
or a salt, solvate or physiologically acceptable derivative thereof;  
(b) lactose and;  
(c) cellobiose octaacetate.

13. (Currently Amended) An inhalable solid pharmaceutical formulation as claimed in claim 12 ~~further comprising one or more of the features described in any one or more of claims 6 to 7~~ wherein the ternary agent is present in an amount of from 0.1 to 20% w/w based on the total weight.

14. (Original) A method of reducing or inhibiting chemical interaction between an active ingredient substance and a carrier susceptible to chemical interaction, which comprises mixing a ternary agent which is a sugar ester with said active ingredient substance and said carrier.

15. (Original) A method of reducing or inhibiting chemical degradation of an active ingredient substance in a formulation comprising a carrier and an active ingredient substance, which method comprises mixing a ternary agent which is a sugar ester with said active ingredient substance and said carrier.

16. (Currently Amended) A method as claimed in claim 14 ~~or 15~~ wherein the ternary agent is cellobiose octaacetate.

17. (Currently Amended) A method as claimed in claim 14 ~~or 15~~ ~~further comprising one or more of the features described in any one or more of claims 4 to 11~~ wherein the carrier is a reducing sugar.

18. (Cancelled).

19. (Currently Amended) A method for treating asthma, chronic obstructive pulmonary diseases (COPD), chronic or wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, or rhinitis, comprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation as claimed in ~~either of~~ claims 12 ~~or 13~~.

20. (New) An inhalable solid pharmaceutical formulation as claimed in claim 13, wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

21. (New) A method as claimed in claim 17, wherein the carrier is lactose.

22. (New) A method as claimed in claim 14, wherein the ternary agent is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.

23. (New) A method as claimed in claim 14, wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

24. (New) A method as claimed in claim 14, wherein said drug substance is selected from:

3-(4-{{6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino}hexyl}oxy}butyl) benzenesulfonamide;  
3-(3-{{7-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl)-amino}heptyl}oxy}propyl)benzenesulfonamide;  
4-{{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and  
4-{{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,  
or a salt, solvate or physiologically acceptable derivative thereof.